P Sonpavde

Nov 1, 2024 | jitc.bmj.com | JAMES GULLEY |Ryan Sullivan |Claire F. Friedman |P Sonpavde

AbstractBackground Invikafusp alfa, a dual T cell agonist, promotes the selective activation and expansion of Vβ6/Vβ10 TCR-expressing CD8+ and CD4+ effector memory T cells, which in nonclinical studies promote potent anti-tumor activity in anti-PD(L)1-resistant solid tumors.1 2Methods START001 is a first-in-human, multicenter Phase 1/2 study evaluating invikafusp as monotherapy in patients with anti-PD(L)1-resistant, antigen-rich solid tumors (TMB-H, MSI-H/dMMR, or virally associated).

Oct 30, 2023 | opmed.doximity.com | Margaret Nichols |Lisa Carey |P Sonpavde

My hand is outstretched. The room is quiet, but with that underlying hum of concentrated activity that occurs when multiple people are intensely and efficiently completing the many tasks necessary for the patient to have a successful outcome. The pace is quick but confident. Without a word, I feel the necessary instrument placed in my hand. My attention to the procedure, removing the thick layer of clotted blood from the surface of the patient’s brain, never varies.

Oct 30, 2023 | opmed.doximity.com | Mohammad Ali Al-Haddad |Sarah Stainko FNP-C |Lisa Carey |P Sonpavde

Physician Mentorship Is Key To Growing an Engaged Advanced Practice Provider WorkforceThe American College of Gastroenterology's annual scientific meeting held each year is a time to be involved, engaged, and present in gastroenterology.

Oct 30, 2023 | opmed.doximity.com | Alexander Yang |Rohit Loomba |Lisa Carey |P Sonpavde

As the autumn foliage gives way to winter snow, The Liver Meeting is upon us once again! This year we are back in the historic Back Bay of Boston ay Hynes Convention Center to meet our friends and colleagues around the world. UCSD is proud and excited to share our research endeavors with researchers and clinicians to help improve care across the globe.

Oct 30, 2023 | opmed.doximity.com | P Sonpavde |Lisa Carey

The ESMO annual conference in 2023 brought the most remarkable advances in the first-line therapy of metastatic urothelial carcinoma (mUC) since the establishment of platinum-based chemotherapy approximately 3 decades ago. The backdrop is that first-line therapy of mUC recently evolved based on the JAVELIN-Bladder-100 Phase III trial to the administration of switch maintenance avelumab (PD-L1 inhibitor) following stable or responding disease with 4-6 cycles of platinum-based chemotherapy.